The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice

Diabetes, Obesity and Metabolism

Volumn 15, Issue 1, 2013, Pages 62-71

  Fosgerau, K ^a   Jessen, L ^a   Lind Tolborg, J ^a   Osterlund T ^a   Schaeffer Larsen K ^a   Rolsted, K ^a   Brorson, M ^a   Jelsing, J ^b   Skovlund Ryge Neerup, T ^a  

^a Zealand Pharma AS   (Denmark)

^b Gubra ApS   (Denmark)

Author keywords

Diabetes; Dual agonist; Gastrin; GLP 1; Glucose control; cell

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIRAGLUTIDE; UNCLASSIFIED DRUG; ZP 3022;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; SINGLE DRUG DOSE; STEREOLOGY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84871169665     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01676.x     Document Type: Article

References (41)

1. World Health Organization. Diabetes. 1-4. 2011. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 18 April 2012.
2. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005; 48: 2221-2228.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
4. Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 2008; 51: 703-713.
5. Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin 2011; 27: 1519-1528.
6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
7. Rolin B, Larsen MO, Gotfredsen CF et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-E752.
8. Gedulin BR, Nikoulina SE, Smith PA et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-2076.
9. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
10. Portha B, Chavey A, Movassat J. Early-life origins of type 2 diabetes: fetal programming of the beta-cell mass. Exp Diabetes Res 2011; 2011: 105076.
11. Rehfeld JF. The endoproteolytic maturation of progastrin and procholecystokinin. J Mol Med (Berl) 2006; 84: 544-550.
12. Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV. The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 2007; 7: 1154-1165.
13. Saillan-Barreau C, Dufresne M, Clerc P et al. Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes 1999; 48: 2015-2021.
14. Rooman I, Lardon J, Flamez D, Schuit F, Bouwens L. Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas. Gastroenterology 2001; 121: 940-949.
15. Rooman I, Lardon J, Bouwens L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 2002; 51: 686-690.
16. Friis-Hansen L. Lessons from the gastrin knockout mice. Regul Pept 2007; 139: 5-22.
17. Suarez-Pinzon WL, Yan Y, Power R, Brand SJ, Rabinovitch A. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 2005; 54: 2596-2601.
18. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 2008; 57: 3281-3288.
19. Tamaki M, Fujitani Y, Uchida T, Hirose T, Kawamori R, Watada H. Combination treatment of db/db mice with exendin-4 and gastrin preserves b-cell mass by stimulating b-cell growth and differentiation. J Diabetes Invest 2010; 1: 172-183.
20. Suarez-Pinzon WL, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice. Cell Transplant 2011; 20: 1343-1349.
21. Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003; 307: 490-496.
22. Paulsen SJ, Vrang N, Larsen LK, Larsen PJ, Jelsing J. Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat 2010; 217: 624-630.
23. Paulsen SJ, Jelsing J, Madsen AN et al. Characterization of beta-cell mass and insulin resistance in diet-induced obese and diet-resistant rats. Obesity (Silver Spring) 2010; 18: 266-273.
24. Bock T, Pakkenberg B, Buschard K. Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 2003; 52: 1716-1722.
25. Puff R, Dames P, Weise M et al. Reduced proliferation and a high apoptotic frequency of pancreatic beta cells contribute to genetically-determined diabetes susceptibility of db/db BKS mice. Horm Metab Res 2011; 43: 306-311.
26. Gapp DA, Leiter EH, Coleman DL, Schwizer RW. Temporal changes in pancreatic islet composition in C57BL/6J-db/db (diabetes) mice. Diabetologia 1983; 25: 439-443.
27. Sturis J, Gotfredsen CF, Romer J et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003; 140: 123-132.
28. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-342.
29. Shimoda M, Kanda Y, Hamamoto S et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011; 54: 1098-1108.
30. Bodvarsdottir TB, Hove KD, Gotfredsen CF et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 2010; 53: 2220-2223.
31. Tellez N, Joanny G, Escoriza J, Vilaseca M, Montanya E. Gastrin treatment stimulates beta-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats. Endocrinology 2011; 152: 2580-2588.
32. Suarez-Pinzon WL, Lakey JR, Brand SJ, Rabinovitch A. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass. J Clin Endocrinol Metab 2005; 90: 3401-3409.
33. Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf) 2011; 201: 405-411.
34. Suarez-Pinzon WL, Lakey JRT, Gotfredsen CF et al. Liraglutide, a long-acting GLP-1 analogue, expands the ß-cell mass of human pancreatic cells implanted in immunodeficient diabetic mice and corrects their diabetes: gastrin potentiates liraglutide's effects (Abstract). Diabetologia 2006; 49(Suppl. 1): 110.
35. Suarez-Pinzon WL, Lakey JR, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant 2008; 17: 631-640.
36. Inge TH, Miyano G, Bean J et al. Reversal of type 2 diabetes mellitus and improvements in cardiovascular risk factors after surgical weight loss in adolescents. Pediatrics 2009; 123: 214-222.
37. Korner J, Inabnet W, Febres G et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009; 33: 786-795.
38. Jacobsen SH, Olesen SC, Dirksen C et al. Changes in gastrointestinal hormone responses, insulin sensitivity and beta-cell function within 2weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22: 1084-1096.
39. Day JW, Ottaway N, Patterson JT et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749-757.
40. Tharakan G, Tan T, Bloom S. Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends Pharmacol Sci 2011; 32: 8-15.
41. Lukasiewicz S, Jonderko K. Partial gastric resection for peptic ulcer--comparison of the effect of variant reconstructive procedures on gastric emptying, gastric acid secretion and gastrin release in the early postoperative period I. Roux-en-Y and Billroth-II gastroenteroanastomosis. East Afr Med J 1994; 71: 407-413.